13 May, 2025 / No comment
Odylia Therapeutics Welcomes Joy Cavagnaro to Board of Directors
Odylia Therapeutics is pleased to announce the appointment of Joy Cavagnaro to its Board of Directors....
12 March, 2025 / No comment
Odylia Therapeutics Announces Partnership with PURA Syndrome Foundation
Atlanta, GA — December 17, 2024 Odylia Therapeutics is excited to announce a new partnership with the PURA Syndrome Foundation (PSF), a nonprofit whose mission is to support and drive research, raise awareness in the general community, as well as connect, educate, serve, and empower......
17 December, 2024 / No comment
Odylia Therapeutics Welcomes Elizabeth Attias to Board of Directors
Odylia Therapeutics is excited to announce the appointment of Elizabeth Attias to its Board of Directors....
22 October, 2024 / No comment
25 September, 2024 / No comment
Odylia Therapeutics Announces Partnership with Smith Kingsmore Syndrome Foundation
Smith Kingsmore Syndrome Foundation (SKSF), a nonprofit whose mission is to improve the lives of all people impacted by Smith-Kingsmore syndrome by accelerating research and connecting our global community. ...
17 September, 2024 / No comment
Odylia Therapeutics Receives Translational Research Award from Foundation Fighting Blindness to Accelerate Development of Gene Therapy for RPGRIP1
Atlanta, GA, May 20, 2024 — Odylia Therapeutics, a nonprofit biotechnology company, received a Translation Research Award for $1.5 million from the Foundation Fighting Blindness to accelerate the development of a novel gene therapy (OT-004) to treat vision loss caused by mutations in the RPGRIP1......
20 May, 2024 / No comment
Odylia CEO & CSO, Ashley Winslow, discusses the Nonprofit Biotech model with Talking Biotech host Kevin Folta
Atlanta, GA — September 9, 2023 A Non-Profit Biotech Model; Therapies for Rare Diseases – Dr. Ashley Winslow By Colabra • Full Transcript • View the Website This episode has two parts. The first part discusses how Odylia Therapeutics is addressing rare disease, using a......
02 October, 2023 / No comment
Odylia contributes to the Affordability Guidance effort spearheaded by the Innovative Genomics Institute
In 2021, IGI’s Public Impact Team launched a year-long Affordability Task Force (ATF) project aimed at solving one of the trickiest challenges for genomic medicines. The report was released in July 2023 and “is the conclusion of a yearlong deliberation by 30 individuals with expertise......
02 October, 2023 / No comment
Odylia Therapeutics Announces Promotion of Ashley Winslow, Ph.D., to CEO
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
11 July, 2023 / No comment
Odylia Therapeutics Announces Appointment of Khandan Baradaran, Ph.D. to Board of Directors
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
04 April, 2023 / No comment
Odylia Therapeutics Announces Partnership with JEM Therapeutics to Accelerate Drug Development Efforts for TECPR2-Related Disease
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
01 March, 2023 / No comment
Andelyn Biosciences and Odylia Therapeutics partner to manufacture novel gene therapy for vision loss
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
31 January, 2023 / No comment
Odylia Therapeutics Announces Appointment of Two New Members to Board of Directors
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
18 August, 2022 / No comment
Odylia Announces Promotion of Ashley Winslow to President and Chief Scientific Officer
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
15 February, 2022 / No comment
Odylia to Host an Update on the RPGRIP1 Gene Therapy Program and Plans for 2022, Feb 3rd
Join us to learn about plans for the RPGRIP1 Gene Therapy Program in 2022. Several key milestones for the RPGRIP1 Program were achieved in 2021. Odylia Therapeutics will present a summary of these benchmarks and what it means for the program. We’ll also discuss the......
21 January, 2022 / No comment
Odylia Therapeutics Granted Orphan Drug and Rare Pediatric Disease Designations by the FDA for OT-004, an Investigational Gene Therapy for RPGRIP1- associated Retinal Dystrophies
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
15 November, 2021 / No comment
Odylia announces new partnership with CLOVES Syndrome Community
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
21 October, 2021 / No comment
Odylia to Host a Free Webinar on RPGRIP1 Gene Therapy Program
Odylia Therapeutics will be discussing our RPGRIP1 Gene Therapy program to treat vision loss in patients diagnosed with Leber Congenital Amaurosis 6 (LCA6). Join us to learn more about Odylia Therapeutics and the progress of our gene therapy program, as well as next steps. Meeting......
15 September, 2021 / No comment
Launch of Odylia’s Newsletter
Odylia is pleased to share our first newsletter....
10 March, 2021 / No comment
Odylia announces new partnership with the SATB2 Gene Foundation
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
24 February, 2021 / No comment
Tiansen Li joins Odylia Advisory Board
“We are very excited to have Tainsen join the Odylia Advisory Board,” said Scott Dorfman, Odylia Therapeutics’ CEO....
09 November, 2020 / No comment
Odylia and Foundation Fighting Blindness will host a 4-part webinar series starting October 8th
Odylia and Foundation Fighting Blindness are hosting a 4-part preclinical and translational research webinar series. The series will focus on genetic technologies and will provide advice and educational materials to researchers in the rare disease space. If you are currently working in or thinking about......
21 September, 2020 / No comment
Sharing Insight for Gene Therapy Manufacturing
Converting vertical information approaches into horizontal solutions for all members of the rare disease community....
04 March, 2020 / No comment
Ashley Winslow joins the Odylia team
Dr. Winslow will oversee scientific operations and strategy development with a focus on expanding partnerships....
05 November, 2019 / No comment
Greg Robinson joins Odylia Advisory Board
Dr. Robinson brings extensive biotech experience in gene therapy, ophthalmology and more...
01 October, 2019 / No comment
Emil Kakkis joins Nonprofit Biotech Odylia Therapeutics Board of Directors
Atlanta, GA August 6, 2019 – Emil Kakkis, MD, PhD, joins the Board of Directors for Odylia Therapeutics. Kakkis is the CEO, President and Founder of Ultragenyx Pharmaceutical Inc., which is committed to developing and commercializing treatments for multiple rare and ultra-rare diseases. He brings......
06 August, 2019 / No comment
PTC Therapeutics Announces Strategic Gene Therapy Licensing Agreement with Odylia Therapeutics
SOUTH PLAINFIELD, N.J., and BOSTON, M.A. – July 1, 2019 – PTC Therapeutics, Inc. (NASDAQ: PTCT) and Odylia Therapeutics today announced a strategic collaboration to develop novel gene therapies in rare inherited retinal diseases (IRDs) utilizing the Anc80 vector system developed by researchers at Massachusetts......
01 July, 2019 / No comment
Odylia Therapeutics CEO Featured on Partners4Access Podcast
Scott Dorfman, Odylia Therapeutics CEO, was recently a featured guest on Partners4Access Weekly Podcast. A recording of the podcast entitled “Rare Disease, Cell and Gene Therapy Weekly Roundup” can be found here. Produced by Partners4Access, global experts in access for orphan drug, cell and gene......
13 June, 2019 / No comment
What is holding back gene therapy for rare diseases?
Odylia CSO Harrison Brown, PhD spoke at the 2019 meeting of the American Society of Gene and Cell Therapy on the issues restricting the development and clinical application of gene therapies for rare genetic diseases. He discussed the specific challenges facing ultra-rare indications, especially those......
02 May, 2019 / No comment
Odylia Presents Gene Therapy Commercialization Workshop
March 26, 2019 (Boston, MA) Odylia Therapeutics Chief Scientific Officer Harrison Brown led a workshop on the challenges and solutions to the development of AAV gene therapies for rare disorders. Held at the 3rd Annual Gene Therapy For Rare Disorders Conference in Boston, MA, this......
05 April, 2019 / No comment
Odylia holds inaugural Gene Therapy Pre‑Competitive Consortium
March 25, 2019 (Boston, MA) The inaugural meeting of the Odylia Gene Therapy Pre-Competitive Consortium has been held at the Massachusetts Eye and Ear campus in Boston, MA. This meeting brought together a select group of thought leaders in the gene therapy field to discuss......
25 March, 2019 / No comment
Odylia co-founder Luk Vandenberghe talks to Nature about bioengineered viruses and the Odylia (non)-business model.
Researcher and entrepreneur Luk Vandenberghe thinks he can transport genes into cells much more efficiently by improving the viral vectors that carry them. He also describes how Odylia can leverage these new technologies to bring therapies for ultra-rare disorders into the clinic. Read the full......
14 December, 2018 / No comment
Odylia CSO speaks to the Charles River World Congress
Odylia CSO Harrison Brown speaks to the Charles River World Congress on the promises and challenges of gene therapy for rare diseases. Video link: Delivering the DNA...
01 November, 2018 / No comment
Odylia CEO speaks at NIH/NCATS conference (video)
Odylia CEO Scott Dorfman presented the Odylia concept to the National Institutes of Health and National Center for Advancing Translational Sciences (NCATS) at a conference on The Growing Promise of Gene Therapy Approaches. Please skip to 4:18:00 to see the Odylia talk and followup panel discussion. ......
20 September, 2018 / No comment
Odylia and co-founder Luk Vandenberghe have been named Xconomy Contrarian Awards finalists
Odylia and co-founder Luk Vandenberghe have been named Xconomy Contrarian Awards finalists After decades of ups and downs, gene therapy’s renaissance is well underway. With one gene therapy, Luxturna, now approved in the U.S., several more are advancing through clinical testing. It’s standard fare now......
27 August, 2018 / No comment
Odylia and Aldevron partner to help more people see
Aldevron and Odylia partner for gene therapy treatments of ultra-rare diseases. Odylia and Aldevron, a contract manufacturing organization specializing in the production of plasmid DNA and other biological agents, have entered into an agreement in which Aldevron is a member of Odylia. Under this agreement,......
27 June, 2018 / No comment
Odylia CEO to speak at the International Symposium on Usher Syndrome
Odylia will be attending the International Symposium on Usher Syndrome July 19-21 in Mainz, Germany. CEO, Scott Dorfman, will be speaking during the scientific presentations on July 20 to present Odylia’s mission to move science to the clinic. Odylia will also present a poster at the......
30 May, 2018 / No comment
Odylia to attend ASGCT 2018
Odylia will be attending the 2018 Annual Meeting of the American Society of Gene and Cell Therapy. We will be meeting with companies and individuals to discuss ways an Odylia partnership can quickly advance therapies for rare disease from the lab to the clinic. Visit......
15 May, 2018 / No comment
Odylia CEO speaks to RARECast about Odylia’s mission
Scott Dorfman, co-founder and CEO of Odylia, speaks to RARECast about what drove the creation of Odylia, how it works as a non-profit, and how we can extend our model to bring more therapies for rare disease to patients. Listen to Interview...
02 April, 2018 / No comment
Odylia co-founder Mass Eye performs first post-approval injection of Luxturna®
Massachusetts Eye and Ear says it has performed the first post-approval injection of the Luxturna®, which treats a form of blindness caused by RPE65 deficiency, otherwise known as RP20. The hospital announced on Tuesday that Jason Comander, the associate director of its inherited retinal disorders......
22 March, 2018 / No comment
Odylia speaks to Xconomy about our plan to resurrect stranded gene therapies
Odylia co-founders Scott Dorman and Luk Vandenberghe speak to Xconomy about the problems keeping gene therapies for rare disease from reaching patients. In this article, Dorfman and Vandenberghe speak about the dozens, if not hundreds, of inherited retinal dystrophies that could be amenable to treatment......
07 March, 2018 / No comment
Odylia to attend Gene Therapy for Rare Disorders 2018
Odylia will be attending the second annual Gene Therapy for Rare Disorders conference in Boston. We will be speaking to companies and individuals about how Odylia can accelerate the development of gene therapies for rare disorders. Visit Website...
05 March, 2018 / No comment
Scientists and advocates announce the formation of Odylia Therapeutics
Odylia Therapeutics, a new nonprofit organization, will bring treatments to clinical trial for people at risk for blindness due to ultra-rare inherited retinal diseases. By leveraging our non-profit status and world-class expertise, we will bring forward therapies for indications which have been left behind by......
02 March, 2018 / No comment